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external agents, lung involvement in non-pulmonary conditions,
or miscellaneous diseases of the lung/respiratory system. Study
measures were assessed over four time periods: 0–12 months pre-
and post-index, 13–24 months post-index, and 25+ months post-
index. Costs of IPF, pulmonary disease (ICD-9-CM 480–519),
and all healthcare services were estimated by category of
resource use. RESULTS: A total of 896 met all patient selection
criteria. They had a mean (SD) age of 48.1 (22.2) years, about
60% were female, and about 44% were white. Approximately
14% of patients died within 12 months of their index date Mean
monthly costs of IPF-related care varied from $148–$314
depending on the follow-up period. Mean monthly costs of all
patient care were more than $4000 higher among IPF versus
non-IPF patients in Florida Medicaid ($4360 vs. $315). CON-
CLUSIONS: Per-patient costs of IPF appear to be considerable
in this population.
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OBJECTIVES: The study evaluated the inﬂuence of tobacco
smoking on direct costs of treatment of chronic obstructive pul-
monary disease (COPD) exacerbations. METHODS: A total of
112 men who underwent treatment of COPD exacerbation in
the Military Institute of Health Service from November 2001 to
October 2002 were included in the study. The patients were qual-
iﬁed into one of three groups: I—never-smoking patients (n =
40), II—former smokers (n = 42); III—active smokers (n = 30).
RESULTS: The mean direct cost of exacerbation treatment was
USD 686.2 (SD 292.3) [group I—642.9 (SD 216.2); group II—
USD 595.4 (SD 193.2); group III—USD 871.1 (SD 401.9)]. No
signiﬁcant differences in treatment costs were found between the
group I and group II. The costs of inhospital treatment of COPD
were signiﬁcantly higher in the group III than in the groups I and
II. A linear correlation was found between each consecutive pack
year of addiction and the costs of exacerbation treatment in the
group III (R = 0.39, R2 = 0.13; p < 0.03). No similar relation-
ship was found in the former smokers’ group. CONCLUSION:
Active tobacco smoking by COPD patients is related to sig-
niﬁcantly higher direct costs of hospitalization due to COPD
exacerbations.
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OBJECTIVES: Assessment of the inﬂuence that a doctor taking
care of a patient has on direct costs of inhospital treatment of
chronic obstructive pulmonary disease (COPD) exacerbation.
METHODS: Medical documentation of patients who had under-
gone treatment of COPD exacerbation in the Military Institute
of Health Service from November 2001 to October 2002 was
studied retrospectively. Direct costs of hospitalization in 8 groups
of patients treated by different doctors (8 specialists, with a
similar length of experience), were compared. RESULTS: A total
of 182 patients were qualiﬁed into 8 study groups, each treated
by a different doctor. The mean hospitalization period was 7.6
(SD 3.1) days. The mean (discounted for 2005) cost of COPD
exacerbation treatment was USD 841.7 (SD 371.0). No statisti-
cally signiﬁcant differences between the groups were found in 
the mean age of the patients, strength of nicotine addiction
(expressed in pack years), severity of the disease and pulmonary
function indices. Differences between the mean direct costs of
treatment by individual doctors amounted to as much as 87%
[USD 690.6 (SD 401.5) vs. USD 1 291.8 (SD 438.6), p < 0.05],
and they resulted mainly from different length of hospitalization
and costs of additional examinations. CONCLUSION: A way of
taking care of a patient by a doctor signiﬁcantly inﬂuences direct
costs of inhospital treatment of COPD exacerbations.
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OBJECTIVES: To assess the cost-effectiveness of Palivizumab, a
prevention against respiratory syncytial virus (RSV) in infants at
high risk, such as premature babies, infants with bronchopul-
monary dysplasia (BPD), and children with congenital heart
disease (CHD) in an Austrian health care setting. METHODS:
A decision tree model was used to estimate the cost-effectiveness
of Palivizumab in high-risk children. The data sources included
published literature, the Palivizumab pivotal trials, ofﬁcial
price/tariff lists and national population statistics. The study was
conducted from the perspective of the health care purchaser
(HCP) (primary) and society (secondary). RESULTS: From the
perspective of the HCP, the incremental cost-effectiveness ratio
(ICER) for preterm infants is €4484/quality adjusted life year
(QALY) without discounting; and becomes €14,439/QALY dis-
counted. For children with BPD the ICER is €6719/QALY
without discounting and increases to €21,672/QALY after dis-
counting. In the CHD indication the ICER is €3115/QALY
undiscounted, while €11,390/QALY discounted. The results
from the society perspective were substantially more cost-effec-
tive in all study populations. In preterm children the ICER is
€1435/QALY without discounting, and becomes €4623/QALY
discounted. For children with BPD the ICER is €4881/QALY
undiscounted and €15,741/QALY after discounting. For the
CHD group the ICER is €251/QALY undiscounted, and
€917/QALY discounted. Sensitivity analyses conﬁrmed the
robustness of the model. CONCLUSION: This study showed
that Palivizumab is a cost-effective prevention against RSV infec-
tions in high-risk infants in Austria under the current health eco-
nomic standards.
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OBJECTIVES: Current treatment guidelines for COPD recom-
mend the use of bronchodilators for the management of patients
with mild to moderate disease and adding inhaled corticosteroids
for severe patients and patients with repeated exacerbations.
This analysis evaluates COPD patients initiating treatment 
with either an inhaled corticosteroid or an anticholinergic to
